CLINICAL COURSE OF CHILDHOOD FAMILIAL DILATED CARDIOMYOPATHY ASSOCIATED WITH SARCOMERIC GENE MUTATIONS  by Alexander, Peta M.A. et al.
E423
JACC April 5, 2011
Volume 57, Issue 14
   CONGENITAL CARDIOLOGY SOLUTIONS
 (ADULT CONGENITAL AND PEDIATRIC CARDIOLOGY)
CLINICAL COURSE OF CHILDHOOD FAMILIAL DILATED CARDIOMYOPATHY ASSOCIATED WITH 
SARCOMERIC GENE MUTATIONS
ACC Poster Contributions
Ernest N. Morial Convention Center, Hall F
Sunday, April 03, 2011, 10:00 a.m.-11:15 a.m.
Session Title: Pediatric Cardiology; Surveillance
Abstract Category: 41 Pediatric Cardiology
Session-Poster Board Number: 1030-427
Authors: Peta M. A. Alexander, Ivan Maccioca, Belinda Chong, Desiree du Sart, Tara Bharucha, Ingrid King, Jeffrey A. Towbin, Robert G. Weintraub, 
The Royal Children’s Hospital, Melbourne, Australia
Background:  Recent evidence suggests a role for sarcomeric gene mutations as a cause of familial dilated cardiomyopathy (DCM). The clinical 
impact on children with these mutations has not been well characterized.
Methods:  We reviewed the clinical course and results of genetic testing of children with familial DCM seen in our center since 1/1/2000. 
The clinical, demographic and genetic information was stored in a dedicated cardiomyopathy database. DNA extracted from blood samples was 
sequenced for ACTC1 CSRP3, PLN, TCAP, TPMI, VCL, TNNT2, TNN13 and MYH7. Standard statistical methods were used to compare children who had 
sarcomeric mutations with the remaining patients.
Results: There were 44 children from 31 families who were diagnosed with familial DCM. Five (11.4%) children from 3 unrelated families were 
found to have mutations in sarcomeric protein genes. Two siblings were heterozygous for cardiac troponin I (TNNI3) mutation Lys36Gln, previously 
reported in autosomal dominant DCM. Siblings from the other families were found to have unreported mutations in MYH7. Two patients from one 
family had the mutation c.2447T>G, leading to a threonine to glycine substitution, [p.W816G] and another patient had the mutation c.1351C>A, 
leading to a cysteine to alanine substitution. [p.Q451K] The median age at diagnosis was 6.4 years (IQR 3.5, 6.8) for those with a sarcomeric 
mutation, compared to 0.5 years for remaining patients (IQR 0.09, 10.7) p=0.37. One of 5 patients with sarcomeric gene abnormality presented 
with heart failure symptoms, compared to 21 of 39 of the remaining patients (p=0.06).Two of 5 patients (40%) with sarcomeric gene abnormality 
reached combined endpoint of death or transplantation, as did 21 of 39 patients (54%) without mutations (p=0.65).
Conclusions:  Sarcomeric gene mutations are an important cause of familial DCM presenting in childhood. Children with these mutations who 
have familial DCM tend to be older and have fewer symptoms at diagnosis than those with other causes of familial DCM. Current clinical and genetic 
screening recommendations need to take account of the potential role of sarcomeric gene mutations in childhood DCM.
